

Request Information

Permalink

Peptide for Induction of Immune Tolerance as Treatment for Systemic Lupus Erythematosus (SLE)

Tech ID: 20403 / UC Case 2008-211-0

SUMMARY

UCLA investigators have invented the D form of an artificial synthetic peptide to induce suppressive T cells that prevent anti-DNA production in mice. The L form of the peptide is administered by injection; however, the new D form of the peptide is designed to be administered orally.

BACKGROUND

Systemic lupus erythematosus is a disease characterized by the production of autoantibodies that react with native cells and tissues, causing inflammation, pain, and damage throughout the body. Increased production of autoantibodies causes immune complex deposition in the kidney, which can result in irreversible renal damage and failure. Edratide, a peptide drug in Phase II clinical trials, is injected subcutaneously in patients to help induce regulatory and suppressive T cells which both downregulate autoimmune responses. Now, however, UCLA investigators are able to orally administer the D form of the peptide.

INNOVATION

UCLA researchers have identified the D form of a peptide called "D-pCons" for the D form of pConsensus. When the L-form of this autoantibody-based peptide is administered to a mouse model of SLE, it induces regulatory T cells to prevent autoantibody production and nephritis. In vitro, the L form also expands regulatory T cells in patients with SLE. The D form of the peptide should be resistant to degradation by acid and proteases, so oral administration is possible. The route of administration and safety should have an advantage over the injected L form of the peptide. Recent studies using the D form show intravenous expression significantly reducing α -DNA production. Additionally, studies demonstrating the efficacy of D-pCons are underway.

APPLICATIONS

- ▶ Treatment for systemic lupus erythematosus by inducing regulatory and suppressive T cells to downregulate autoimmune responses

ADVANTAGES

- ▶ Oral route of administration with increased ease and increased safety
- ▶ D form of peptide is resistant to acid and protease degradation

STATE OF DEVELOPMENT

D-pCons has been conceptualized, synthesized and tested in initial screens for effectiveness. Studies are currently being conducted by oral administration of the D peptide form to mouse models of SLE.

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	8,492,347	07/23/2013	2008-211

CONTACT

UCLA Technology Development Group
 ncd@tdg.ucla.edu
 tel: 310.794.0558.



INVENTORS

- ▶ Hahn, Bevra H.

OTHER INFORMATION

KEYWORDS

therapeutic, systemic lupus erythematosus, SLE, autoantibodies, inflammation, downregulation, D-pCons, PConsensus, nephritis, suppressive, regulatory, T cells

CATEGORIZED AS

- ▶ Medical
- ▶ Therapeutics

RELATED CASES

2008-211-0

UCLA Technology Development Group

10889 Wilshire Blvd., Suite 920, Los Angeles, CA 90095

tdg.ucla.edu

Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu

© 2010 - 2015, The Regents of the University of California

[Terms of use](#)

[Privacy Notice](#)

